Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Itamar Raz

Showing results (241-250 of 254) with videos related to

Pageof 26
Sort By:
Circulation|January 28, 2020
Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 TrialThomas A Zelniker, Marc P Bonaca, Remo H M Furtado, et al.
Circulation|August 16, 2020
Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58Marc P Bonaca, Stephen D Wiviott, Thomas A Zelniker, et al.
The New England Journal of Medicine|November 13, 2018
Dapagliflozin and Cardiovascular Outcomes in Type 2 DiabetesStephen D Wiviott, Itamar Raz, Marc P Bonaca, et al.
Circulation|March 19, 2019
Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial InfarctionRemo H M Furtado, Marc P Bonaca, Itamar Raz, et al.
European Heart Journal|August 18, 2022
A polygenic risk score predicts atrial fibrillation in cardiovascular diseaseNicholas A Marston, Amanda C Garfinkel, Frederick K Kamanu, et al.
Circulation|May 5, 2022
Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 TrialRemo H M Furtado, Itamar Raz, Erica L Goodrich, et al.
Circulation. Genomic and Precision Medicine|January 12, 2021
Genetic Risk Score to Identify Risk of Venous Thromboembolism in Patients With Cardiometabolic DiseaseNicholas A Marston, Giorgio E M Melloni, Yared Gurmu, et al.
The Lancet. Diabetes & Endocrinology|June 15, 2019
Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trialOfri Mosenzon, Stephen D Wiviott, Avivit Cahn, et al.
Diabetes Care|July 8, 2021
The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58Ofri Mosenzon, Stephen D Wiviott, Hiddo J L Heerspink, et al.
Diabetes Care|August 23, 2022
Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 TrialOfri Mosenzon, Itamar Raz, Stephen D Wiviott, et al.
Pageof 26

Showing results (241-250 of 254) with videos related to

Sort By:
Pageof 26
Circulation|January 28, 2020
Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 TrialThomas A Zelniker, Marc P Bonaca, Remo H M Furtado, et al.
Circulation|August 16, 2020
Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58Marc P Bonaca, Stephen D Wiviott, Thomas A Zelniker, et al.
The New England Journal of Medicine|November 13, 2018
Dapagliflozin and Cardiovascular Outcomes in Type 2 DiabetesStephen D Wiviott, Itamar Raz, Marc P Bonaca, et al.
Circulation|March 19, 2019
Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial InfarctionRemo H M Furtado, Marc P Bonaca, Itamar Raz, et al.
European Heart Journal|August 18, 2022
A polygenic risk score predicts atrial fibrillation in cardiovascular diseaseNicholas A Marston, Amanda C Garfinkel, Frederick K Kamanu, et al.
Circulation|May 5, 2022
Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 TrialRemo H M Furtado, Itamar Raz, Erica L Goodrich, et al.
Circulation. Genomic and Precision Medicine|January 12, 2021
Genetic Risk Score to Identify Risk of Venous Thromboembolism in Patients With Cardiometabolic DiseaseNicholas A Marston, Giorgio E M Melloni, Yared Gurmu, et al.
The Lancet. Diabetes & Endocrinology|June 15, 2019
Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trialOfri Mosenzon, Stephen D Wiviott, Avivit Cahn, et al.
Diabetes Care|July 8, 2021
The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58Ofri Mosenzon, Stephen D Wiviott, Hiddo J L Heerspink, et al.
Diabetes Care|August 23, 2022
Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 TrialOfri Mosenzon, Itamar Raz, Stephen D Wiviott, et al.
Pageof 26